Dr. Mamounas on Patient Selection for Endocrine Therapy

Eleftherios P. Mamounas, MD
Published: Friday, Aug 07, 2015



Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, discusses which patients with breast cancer are most likely to benefit from endocrine therapy.

In the frontline setting, patients are selected by the expressing estrogen receptor, Mamounas says. Patients who are estrogen receptor (ER)-positive are more likely to benefit from endocrine therapy versus those who are ER-negative. However, it is unclear which patients will benefit from delayed endocrine therapy. Several clinical trials are examining this and researchers are awaiting the results.

Another frequently used factor for determining treatment is tumor size and node status, Mamounas explains. For example, patients with positive nodes upfront, even after five years, have a significantly higher chance of benefitting from endocrine therapy than those with negative nodes. For patients with node-negative disease, oncologists can sub-stratify them with genomic tests.



Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, discusses which patients with breast cancer are most likely to benefit from endocrine therapy.

In the frontline setting, patients are selected by the expressing estrogen receptor, Mamounas says. Patients who are estrogen receptor (ER)-positive are more likely to benefit from endocrine therapy versus those who are ER-negative. However, it is unclear which patients will benefit from delayed endocrine therapy. Several clinical trials are examining this and researchers are awaiting the results.

Another frequently used factor for determining treatment is tumor size and node status, Mamounas explains. For example, patients with positive nodes upfront, even after five years, have a significantly higher chance of benefitting from endocrine therapy than those with negative nodes. For patients with node-negative disease, oncologists can sub-stratify them with genomic tests.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x